|
| Press Releases |
|
 |
|
| Thursday, March 31, 2016 |
|
|
Eisai Transfer the Rights to Investigational Anticancer Agent E7777 for European, U.S and Certain Emerging Markets to Dr. Reddy's Laboratories |
| Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the exclusive worldwide development and marketing rights (excluding Japan and Asia) for its investigational anticancer agent E7777 to Dr. Reddy's Laboratories Ltd. more info >> |
|
| Wednesday, March 30, 2016 |
|
|
Eisai Co., Ltd. and Ajinomoto Co., Inc. Announce Establishment of Gastrointestinal Specialty Pharma EA Pharma Co., Ltd. |
| Eisai Co., Ltd. and Ajinomoto Co., Inc. announced today that based on the integration agreement signed and announced on October 15, 2015, the gastrointestinal specialty pharma EA Pharma Co., Ltd. will be established through the splitting off of a portion of Eisai's gastrointestinal disease treatment. more info >> |
|
|
Eisai's Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2016 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that based on recent trends in business results, etc., the company has revised its full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016) previously announced on February 2, 2016. more info >> |
|
|
Eisai's Notice Concerning Shelf Registration for Issuance of Stock Options |
| Eisai Co., Ltd. ("the Company") today filed a shelf registration statement with the Kanto Local Finance Bureau for issuance of stock options in accordance with the Company's "Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders" ("the Policy"). more info >> |
|
| Tuesday, March 29, 2016 |
|
|
Eisai's In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) Approved in Japan |
| Eisai Co., Ltd. announced today that its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) has been approved in Japan as an adjunctive therapy for partial-onset seizures or primary generalized tonic-clonic seizures in patients with epilepsy showing inadequate response to other AEDs. more info >> |
|
| Tuesday, March 22, 2016 |
|
|
Eisai Withdraws New Drugs Application for Mecobalamin Ultra-High Dose Preparation as Treatment for Amyotrophic Lateral Sclerosis |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has withdrawn its new drug application for ultra-high dose Mecobalamin development code: E0302) as a treatment for amyotrophic lateral sclerosis (ALS) in Japan. more info >> |
|
| Thursday, March 17, 2016 |
|
|
Notice Regarding Discontinuation of Sales and Voluntary Recall of Egg White Lysozyme Preparation Neuzym |
| Eisai Co., Ltd. announced today that its pharmaceutical manufacturing and marketing subsidiary Sannova Co., Ltd. has been informed the results of deliberation of the Committee on Reevaluation of the Pharmaceutical Affairs and Food Sanitation Council's meeting held on March 17 regarding the egg white lysozyme preparation Neuzym (lysozyme hydrochloride, "lysozyme") which had been submitted for reevaluation. more info >> |
|
| Monday, February 15, 2016 |
|
|
Eisai and Sysmex Enter Comprehensive Agreement to Create Next-Generation Diagnostic Reagents in the Field of Dementia |
| Eisai Co., Ltd. and Sysmex Corporation jointly announced that the two companies have entered into a comprehensive non-exclusive collaboration agreement aimed at the creation of new diagnostics in the field of dementia. more info >> |
|
| Friday, February 12, 2016 |
|
|
Phase III Trial Results of Eisai's Anticancer Agent Halaven(R) in Soft Tissue Sarcoma Published in The Lancet |
| Eisai Co., Ltd. announced today that the results of a Phase III clinical study (Study 309) of its in-house discovered and developed anticancer agent Halaven(R) (eribulin mesylate) in patients with locally advanced, recurrent or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma)[1] have been published in the online version of The Lancet. more info >> |
|
| Monday, February 1, 2016 |
|
|
Eisai Acquires Exclusive License from Huya Bioscience International to Develop and Market HDAC Inhibitor HBI-8000 in Japan and Other Asian Countries |
| Eisai Co., Ltd. (TSE:4523) announced today that Eisai has entered into an exclusive license agreement with HUYA Bioscience International, LLC (San Diego, CA, USA) to develop and market the oral histone deacetylase (HDAC) inhibitor HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Naoris Protocol Announces Upcoming TGE for $NAORIS 
Jul 30, 2025 22:00 HKT/SGT
|
|
|
Introducing the Meshy 5 Preview: Smarter AI, Cleaner Models, Bigger Animation Potential
Jul 30, 2025 22:41 JST
|
|
|
New Report Reveals Key Considerations For Successful Distribution Onboarding
Jul 30, 2025 21:00 HKT/SGT
|
|
|
Wintermar Offshore (WINS:JK) Reports 1H2025 Results
Jul 30, 2025 19:56 HKT/SGT
|
|
|
Hong Kong Shopping Festival Returns in August with Bigger and Better 2nd Edition
Jul 30, 2025 18:29 HKT/SGT
|
|
|
Production, Sales and Export Results for June, 2025
Jul 30, 2025 18:24 JST
|
|
|
Sales, Production, and Export Results for the First Half of 2025
Jul 30, 2025 18:06 JST
|
|
|
Ongoing Share Buybacks Demonstrate Confidence, Shoucheng Holdings Boosts Market Expectations with Concrete Action
Jul 30, 2025 11:00 HKT/SGT
|
|
|
Collaborative Development of Ultra-Compact and Lightweight Satellite Communication User Terminals for Mobility with Mitsubishi Chemical, NICT, and TECHLAB
Jul 30, 2025 11:00 JST
|
|
|
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases
Jul 29, 2025 23:13 HKT/SGT
|
|
|
Mitsubishi Heavy Industries Concludes Agreement with Modius to Provide DCIM Solutions for Data Centers Worldwide
Jul 29, 2025 20:00 JST
|
|
|
Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture Excellence
Jul 29, 2025 16:00 HKT/SGT
|
|
|
Set at the Osaka-Kansai Expo venue! Detailed program announced for the "OSAKA JAPAN SDGs Forum"
Jul 29, 2025 14:30 JST
|
|
|
GTJAI Achieved 'Carbon Neutrality' at Operational Level for the Third Consecutive Year
Jul 29, 2025 13:15 HKT/SGT
|
|
|
Unitree Races Toward IPO as Robot Applications Accelerate: Shoucheng Holdings Unlocks Dual-Engine Gains
Jul 29, 2025 11:30 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
